Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hot Spots In 2023: US FDA Goal Dates Portend Battles In Diseases From RSV To Ulcerative Colitis

Feb 06 2023

• By Bridget Silverman

• Source: Shutterstock

Related Content

Dispute Resolution: Ardelyx Eyes Tenapanor Resubmission Following Successful Appeal To FDA

Jan 04 2023

Bountiful Approvals May Be Ahead As FDA Starts 2023 With Almost 60 Novel Agents Under Review

Feb 06 2023

Keeping Track: RSV Vaccine Race Heats Up Between Pfizer And GSK; Another J&J Bispecific For Myeloma

Dec 11 2022

IBD Market Snapshot: New Medicines Try To Address Patient, Physician Demands

Nov 15 2022

Santhera Finalizes Vamorolone Filings And Now Seeks Funds

Oct 31 2022

Can UCB Make Its Mark In Myasthenia Gravis?

May 11 2022

Genmab Confident It Has Edge Over Roche In Bispecific Battle

Jun 17 2022

RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates

Jun 24 2022

A Duchenne Breakthrough Awaits In 2023 - But Risks Remain For Sarepta And US FDA

Dec 06 2022

Related Companies

Eli Lilly and Company

Johnson & Johnson

Pfizer Inc.

Bristol Myers Squibb Company

GSK plc

AstraZeneca PLC

Janssen Pharmaceutical Cos.

Moderna, Inc.

Bavarian Nordic A/S

Swedish Orphan Biovitrum AB

Genmab A/S

Genentech, Inc.

UCB S.A.

argenx N.V.

Alexion Pharmaceuticals Inc.

Santhera Pharmaceuticals

Sarepta Therapeutics, Inc.

Roche Holding AG

Sage Therapeutics, Inc.

Biogen, Inc.

Fabre-Kramer Pharmaceuticals

Additional Topics

United States Drug Review Drug Approval Standards Regulation US FDA Performance Tracker Pink Sheet Perspectives BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window